Cargando…

Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease

OBJECTIVE: Microglia play a pivotal role in the initiation and progression of Alzheimer's disease (AD). We here tested the therapeutic hypothesis that the Ca(2+)‐activated potassium channel KCa3.1 constitutes a potential target for treating AD by reducing neuroinflammation. METHODS: To determin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Lee‐Way, Lucente, Jacopo Di, Nguyen, Hai M., Singh, Vikrant, Singh, Latika, Chavez, Monique, Bushong, Trevor, Wulff, Heike, Maezawa, Izumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469250/ https://www.ncbi.nlm.nih.gov/pubmed/31019997 http://dx.doi.org/10.1002/acn3.754

Ejemplares similares

Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease
por: Maezawa, Izumi, et al.
Publicado: (2012)

Differential Kv1.3, KCa3.1, and Kir2.1 expression in “classically” and “alternatively” activated microglia
por: Nguyen, Hai M., et al.
Publicado: (2016)

Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease
por: Paka, Latha, et al.
Publicado: (2017)

Effect of the KCa3.1 blocker, senicapoc, on cerebral edema and cardiovascular function after cardiac arrest — A randomized experimental rat study
por: Hansen, Frederik Boe, et al.
Publicado: (2021)

KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
por: Brown, Brandon M., et al.
Publicado: (2018)

Radiation Increases Functional KCa3.1 Expression and Invasiveness in Glioblastoma
por: D’Alessandro, Giuseppina, et al.
Publicado: (2019)

Novel Phenolic Inhibitors of Small/Intermediate-Conductance Ca(2+)-Activated K(+) Channels, KCa3.1 and KCa2.3
por: Oliván-Viguera, Aida, et al.
Publicado: (2013)

KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment
por: D'Alessandro, Giuseppina, et al.
Publicado: (2016)

Contribution of the KCa3.1 channel–calmodulin interactions to the regulation of the KCa3.1 gating process
por: Morales, Patricia, et al.
Publicado: (2013)

Biophysical basis for Kv1.3 regulation of membrane potential changes induced by P2X4‐mediated calcium entry in microglia
por: Nguyen, Hai M., et al.
Publicado: (2020)

Involvement of KCa3.1 channel activity in immediate perioperative cognitive and neuroinflammatory outcomes
por: Saxena, Sarah, et al.
Publicado: (2023)

The Ca(2+)-Activated K(+) Channel KCa3.1 as a Potential New Target for the Prevention of Allograft Vasculopathy
por: Chen, Yi-Je, et al.
Publicado: (2013)

Genetic KCa3.1-Deficiency Produces Locomotor Hyperactivity and Alterations in Cerebral Monoamine Levels
por: Lambertsen, Kate Lykke, et al.
Publicado: (2012)

KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo
por: D'Alessandro, G, et al.
Publicado: (2013)

The calcium-activated potassium channel KCa3.1 is an important modulator of hepatic injury
por: Sevelsted Møller, Linda, et al.
Publicado: (2016)

KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia/macrophages
por: Grimaldi, A, et al.
Publicado: (2016)

Conditional KCa3.1-transgene induction in murine skin produces pruritic eczematous dermatitis with severe epidermal hyperplasia and hyperkeratosis
por: Lozano-Gerona, Javier, et al.
Publicado: (2020)

Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke
por: Chen, Yi‐Je, et al.
Publicado: (2017)

Blocking KCa3.1 Channels Increases Tumor Cell Killing by a Subpopulation of Human Natural Killer Lymphocytes
por: Koshy, Shyny, et al.
Publicado: (2013)

Transcriptomic and glycomic analyses highlight pathway-specific glycosylation alterations unique to Alzheimer’s disease
por: Tang, Xinyu, et al.
Publicado: (2023)

Topical Delivery of Senicapoc Nanoliposomal Formulation for Ocular Surface Treatments
por: Phua, Jie Liang, et al.
Publicado: (2018)

Endothelial KCa channels: Novel targets to reduce atherosclerosis-driven vascular dysfunction
por: Vera, O. Daniel, et al.
Publicado: (2023)

Treatment with senicapoc in a porcine model of acute respiratory distress syndrome
por: Petersen, Asbjørn G., et al.
Publicado: (2021)

Investigating CFTR and KCa3.1 Protein/Protein Interactions
por: Klein, Hélène, et al.
Publicado: (2016)

IK Channel-Independent Effects of Clotrimazole and Senicapoc on Cancer Cells Viability and Migration
por: Zuccolini, Paolo, et al.
Publicado: (2023)

Characterization of the PCMBS-dependent modification of KCa3.1 channel gating
por: Bailey, Mark A., et al.
Publicado: (2010)

Modulation of Retrograde Trafficking of KCa3.1 in a Polarized Epithelium
por: Lee, Bob Shih-Liang, et al.
Publicado: (2017)

KCa3.1 Impairment Is Not Just a Slow Afterthought in Epilepsy
por: Gross, Christina
Publicado: (2020)

A validated UHPLC-MS/MS method for rapid determination of senicapoc in plasma samples
por: Sørensen, Lambert K., et al.
Publicado: (2021)

KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis
por: Huang, Chunling, et al.
Publicado: (2014)

KCa3.1 as an Effective Target for Inhibition of Growth and Progression of Intrahepatic Cholangiocarcinoma
por: Song, Penghong, et al.
Publicado: (2017)

The Trials and Tribulations of Structure Assisted Design of K(Ca) Channel Activators
por: Shim, Heesung, et al.
Publicado: (2019)

Riluzole and novel naphthalenyl substituted aminothiazole derivatives prevent acute neural excitotoxic injury in a rat model of temporal lobe epilepsy
por: Kyllo, Thomas, et al.
Publicado: (2023)

Regulatory role of KCa3.1 in immune cell function and its emerging association with rheumatoid arthritis
por: Lin, Yi, et al.
Publicado: (2022)

Histidine phosphorylation relieves copper inhibition in the mammalian potassium channel KCa3.1
por: Srivastava, Shekhar, et al.
Publicado: (2016)

KCa3.1 ion channel: A novel therapeutic target for corneal fibrosis
por: Anumanthan, Govindaraj, et al.
Publicado: (2018)

KCa3.1 Mediates Dysregulation of Mitochondrial Quality Control in Diabetic Kidney Disease
por: Huang, Chunling, et al.
Publicado: (2021)

Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) causes seizure activity in larval zebrafish via antagonism of γ-aminobutyric acid type A receptor α1β2γ2
por: Mundy, Paige C., et al.
Publicado: (2023)

Expression and Role of the Intermediate-Conductance Calcium-Activated Potassium Channel KCa3.1 in Glioblastoma
por: Catacuzzeno, Luigi, et al.
Publicado: (2012)

KCa3.1 and TRPM7 Channels at the Uropod Regulate Migration of Activated Human T Cells
por: Kuras, Zerrin, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bi30ptbees4cdp43tcape99sv6